Athira Pharma, Inc. (“Athira”) (NASDAQ: ATHA) allegedly omitted crucial truths about its CEO and President in the Registration Statement for its initial public offering (IPO), eventually causing investors to lose significant amounts of money. If you purchased or acquired ATHA common stock pursuant to or traceable to the IPO, please contact Keller Rohrback’s securities team at investor@kellerrohrback.com, (800) 776-6044, or by using the secure form on this page.

Athira announced after close of trading on June 17, 2021 that the Athira Board had placed its CEO and President, Dr. Leen Kawas, on temporary leave in light of claims that she had falsified research results in various academic papers. This news caused Athira’s stock to plunge approximately 40% from $18.24 to $11.15 per share—well below the $17.00 IPO price.

Keller Rohrback and co-counsel Longman Law, P.C. filed a class action lawsuit against Athira Pharma, Inc., certain officers and directors, and the underwriters of the September 2020 Initial Public Offering (“IPO”) of Athira common stock. The suit, entitled Timothy Slyne, et al. v. Athira Pharma, Inc., et al., was filed in the Western District of Washington on behalf of purchasers of ATHA common stock who either purchased shares in the September 2020 IPO or on the open market that can be traced back to the IPO. 

Keller Rohrback’s lawsuit seeks remedies for investors harmed by Athira’s actions. To learn more or join the lawsuit, please contact us at investor@kellerrohrback.com or (800) 776-6044 for a no-cost consultation.  

About Keller Rohrback L.L.P.

With offices in Seattle, Phoenix, New York, Oakland, Santa Barbara, and Missoula, Keller Rohrback serves as lead and co-lead counsel in class actions throughout the country. The firm has a track record for holding corporations accountable for wrongdoing and has achieved large settlements on behalf of its clients, including a $142 million settlement in the Wells Fargo Unauthorized Accounts Scandal.

Attorney advertising. Prior results do not guarantee a similar outcome. Please see krcomplexlit.com for more details.